http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113912679-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06b4ca0ab0f286da36c46f9b75e813a7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate | 2021-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c39e32c3d10d8265bb30ece38b67f0fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11330eb8580bc3aa70e7828206b99f29 |
| publicationDate | 2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113912679-A |
| titleOfInvention | Polypeptide targeting androgen receptor, application thereof and medicament for preventing and treating prostatic cancer |
| abstract | The invention provides a polypeptide targeting androgen receptor, application thereof and a medicament for preventing and treating prostatic cancer, belonging to the technical field of protein polypeptide. The polypeptide has stronger binding capacity with AR-V7 protein, can effectively inhibit cell proliferation when delivered to AR positive and AR-V7 positive prostate cancer cells, and has the capacity of degrading AR and AR-V7 under the condition of MDM 2. Therefore, the polypeptide can be applied to the preparation of medicines for preventing and/or treating prostate cancer or reagents for degrading AR and/or AR-V7 protein. Compared with the existing targeted drugs, the PROTAC drug can provide a new treatment strategy for treating drug-resistant and late castration-resistant prostate tumors, particularly can solve the drug-resistant problem of CRPC patients caused by AR splicers such as AR-V7 and the like, and fills the blank of drugs targeting the DNA binding domain of AR in the global range. |
| priorityDate | 2021-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.